Crossmark

Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort

Crossref DOI link: https://doi.org/10.1186/s12879-018-3367-3

Published Online: 2018-09-14

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Adland, Emily

Jesuthasan, Gerald

Downs, Louise

Wharton, Victoria

Wilde, Gemma

McNaughton, Anna L.

Collier, Jane

Barnes, Eleanor

Klenerman, Paul

Andersson, Monique

Jeffery, Katie

Matthews, Philippa C. http://orcid.org/0000-0002-4036-4269
Funding

Funding for this research was provided by:

Wellcome Trust (110110)
License Information

Text and Data Mining valid from 2018-09-14
More Information

Article History

Received: 2 November 2017

Accepted: 30 August 2018

First Online: 14 September 2018

Authors’ information

: EB is the lead for the UK STOP-HCV program. PCM is a Wellcome Trust Clinical Research Fellow investigating chronic viral hepatitis infection.

: No specific ethics approval was required for this study as it was undertaken as a quality improvement study using anonymised data from within a clinical microbiology laboratory and hepatology service.

: Not applicable.

: MA has received research funding from Gilead. PCM is a member of BMC Infectious Diseases Editorial Board (assistant editor).

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.